Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

Diabetes, Obesity and Metabolism

Volumn 16, Issue 3, 2014, Pages 215-222

  Macha, S ^a   Mattheus, M ^b   Halabi, A ^c   Pinnetti, S ^b   Woerle, H J ^b   Broedl, U C ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c CRS Clinical Research Services GmbH   (Germany)

Author keywords

Diabetes; Empagliflozin; Pharmacodynamics; Pharmacokinetics; Renal impairment; SGLT2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; ERYTHEMA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHARMACODYNAMICS; PRURITUS; SEVERE RENAL IMPAIRMENT;

DIABETES; EMPAGLIFLOZIN; PHARMACODYNAMICS; PHARMACOKINETICS; RENAL IMPAIRMENT; SGLT2 INHIBITOR;

ADULT; AGED; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL INSUFFICIENCY; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84893727925     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12182     Document Type: Article

References (14)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
2. WHO. Ten facts about diabetes. Available from URL: http://www.who.int/features/factfiles/diabetes/facts/en/index4.html. Accessed 24 September 2012.
3. Cefalu WT. Evolving treatment strategies for the management of type 2 diabetes. Am J Med Sci 2012; 343: 21-26.
4. DeFronzo RA. Overview of newer agents: where treatment is going. Am J Med 2010; 123: S38-S48.
5. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
7. Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A et al. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area. BMC Nephrol 2012; 13: 87.
8. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009; 31: 2608-2617.
9. Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis - a postion statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53: 915-920.
10. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
11. Seman L, Macha S, Nehmiz G et al. Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharm in Drug Dev 2013; 2: 152-161.
12. Heise T, Seewaldt-Becker E, Macha S et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 613-621.
13. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 721-728.
14. Rosenstock J, Jelaska A, Seman L, Pinnetti S, Hantel S, Woerle HJ. Efficacy and safety of BI 10773, a new sodium glucose cotransporter (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes 2011; 60: A271[989-P].